Chimerix Inc (CMRX) News

Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024

DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose...

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., April 16, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced that on April 10...

Chimerix Appoints Marc D. Kozin to Board of Directors

DURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose...

Form S-3 - Registration statement under Securities Act of 1933

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update

– ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 –...

Chimerix to Present at TD Cowen 44th Annual Health Care Conference

DURHAM, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose...

Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024

DURHAM, N.C., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities